This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tremblay, C. L.
Right arrow Articles by Hirsch, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tremblay, C. L.
Right arrow Articles by Hirsch, M. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2003, p. 3644-3646, Vol. 47, No. 11
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.11.3644-3646.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Favorable Interactions between Enfuvirtide and 1-ß-D-2,6-Diaminopurine Dioxolane In Vitro

Cécile L. Tremblay,1,2 Danielle L. Poulin,1 Jennifer L. Hicks,1 Subajini Selliah,2 Annie Chamberland,2 Françoise Giguel,1 Christopher S. Kollmann,1 Ting Chao Chou,3 Huajin Dong,3 and Martin S. Hirsch1*

Massachusetts General Hospital, Infectious Diseases Unit, Harvard Medical School, Boston, Massachusetts,1 Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada,2 Memorial Sloan-Kettering Cancer Center, New York, New York3

Received 2 May 2003/ Returned for modification 30 June 2003/ Accepted 4 August 2003

We evaluated the in vitro anti-human immunodeficiency virus type 1 (HIV-1) interactions between 1- ß-D-2,6-diaminopurine dioxolane (DAPD) and enfuvirtide (T-20) against clinical isolates sensitive and resistant to reverse transcriptase and protease inhibitors. Interactions between T-20 and DAPD were synergistic to nearly additive, with combination index values ranging from 0.53 to 1.06 at 95% inhibitory concentrations. These studies suggest that a combination of T-20 and DAPD might be useful in the treatment of antiretroviral drug-experienced patients.

* Corresponding author. Mailing address: Centre Hospitalier de l'Université de Montréal, Pavillon Jeanne-Mance, Bureau 7-355, Montréal, Qc H2W 1T8, Canada. Phone: (514) 890-8000, ext. 14613. Fax: (514) 412-7234. E-mail: c.tremblay{at}umontreal.ca.

Antimicrobial Agents and Chemotherapy, November 2003, p. 3644-3646, Vol. 47, No. 11
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.11.3644-3646.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Tremblay, C. L., Giguel, F., Guan, Y., Chou, T.-C., Takashima, K., Hirsch, M. S. (2005). TAK-220, a Novel Small-Molecule CCR5 Antagonist, Has Favorable Anti-Human Immunodeficiency Virus Interactions with Other Antiretrovirals In Vitro. Antimicrob. Agents Chemother. 49: 3483-3485 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»